Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
2005-2-7
pubmed:abstractText
Functional and genomic approaches can be integrated to screen efficiently for pathogenic alleles in founder populations. We applied such approaches to analysis of the cancer-associated cell cycle regulator CHEK2 in the Ashkenazi Jewish population. We first identified two extended haplotypes at CHEK2 that co-segregated with breast cancer in high-risk families. We sequenced CHEK2 in a case representing each haplotype and discovered two novel amino acid substitutions, CHEK2.S428F in the kinase domain and CHEK2.P85L in the N-terminal region. To assay these alleles for loss of CHEK2 function, we tested their capacity to complement Rad53 deletion in Saccharomyces cerevisiae. CHEK2.S428F failed to complement Rad53 and thus largely abrogates normal CHEK2 function, whereas CHEK2.P85L complemented Rad53 as well as did wild-type CHEK2. Epidemiologic analyses were concordant with the functional tests. Frequencies of CHEK2.S428F heterozygotes were 2.88% (47/1632) among female breast cancer patients not selected for family history or age at diagnosis and 1.37% (23/1673) among controls (OR=2.13, 95% CI [1.26, 3.69], P=0.004), whereas frequencies of CHEK2.P85L were 0.92% among cases and 0.83% among controls. On the basis of the experience of mothers, sisters and daughters of probands, breast cancer risk due to CHEK2.S428F was estimated as 0.17 (+/-0.08) by age 60. We conclude that CHEK2.S428F increases breast cancer risk approximately 2-fold among Ashkenazi Jewish women, whereas CHEK2.P85L is a neutral allele. In general, these results suggest that selecting probands with extended haplotypes that co-segregate with disease can improve the efficiency of resequencing efforts and that quantitative complementation tests in yeast can be used to evaluate variants in genes with highly conserved function.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Feb
pubmed:issn
0964-6906
pubmed:author
pubmed:issnType
Print
pubmed:day
15
pubmed:volume
14
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
555-63
pubmed:dateRevised
2011-11-2
pubmed:meshHeading
pubmed-meshheading:15649950-Amino Acid Substitution, pubmed-meshheading:15649950-Breast Neoplasms, pubmed-meshheading:15649950-Cell Cycle Proteins, pubmed-meshheading:15649950-Female, pubmed-meshheading:15649950-Gene Frequency, pubmed-meshheading:15649950-Genetic Complementation Test, pubmed-meshheading:15649950-Genetic Predisposition to Disease, pubmed-meshheading:15649950-Haplotypes, pubmed-meshheading:15649950-Heterozygote, pubmed-meshheading:15649950-Humans, pubmed-meshheading:15649950-Jews, pubmed-meshheading:15649950-Male, pubmed-meshheading:15649950-Mutation, pubmed-meshheading:15649950-Protein-Serine-Threonine Kinases, pubmed-meshheading:15649950-Risk Factors, pubmed-meshheading:15649950-Saccharomyces cerevisiae, pubmed-meshheading:15649950-Saccharomyces cerevisiae Proteins, pubmed-meshheading:15649950-Sequence Deletion
pubmed:year
2005
pubmed:articleTitle
Functional and genomic approaches reveal an ancient CHEK2 allele associated with breast cancer in the Ashkenazi Jewish population.
pubmed:affiliation
Department of Medicine (Medical Genetics) and Genome Sciences, University of Washington, Seattle, WA 98195-7720, USA.
pubmed:publicationType
Journal Article, Research Support, U.S. Gov't, P.H.S., Research Support, Non-U.S. Gov't, Research Support, N.I.H., Extramural